IDH mutations are the most common oncogenic driver mutations in glioma and AML,8, 27 and IDH inhibitors approved by the FDA and those in clinical trials mainly target IDH active‐site mutations in these two cancers. The gene discussed is IDH2; the disease is acute myeloid leukemia.